Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care

International Journal of COPD

Volumn 4, Issue 1, 2009, Pages 45-53

  Llor, Carles ^a,i   Hernández, Silvia ^a   Ribas, Anna ^b   Álvarez, Carmen ^c   Cots, Josep Maria ^d   Bayona, Carolina ^e   González, Isabel ^f   Miravitlles, Marc ^g   Ansa, Xabier ^h   Bonamaison, Montse ^c   Cereceda, Marta ^c   Deniel, Joan ^c   Espina, Jordi ^c   Espinàs, Jordi ^b   Ezquerra, Teresa ^c   Gifré, Josep M ^b   Grifoll, Ferran ^h   Pedrerol, M Mar ^c   Planes, Albert ^b   Puiol, Xavier ^c   Ribas, Montserrat ^c   Rodríguez, Anna ^b   Salla, Rosa M ^b   Valldosera, Jordi ^h   Vilajoana, Meritxell ^b   Vilamú, Maria ^c   more..

^a Primary Care Centre Jaume I   (Spain)

^b Primary Care Centre Santa Eugènia de Berga   (Spain)

^c Primary Care Centre Manlleu   (Spain)

^d Primary Healthcare Centre La Marina   (Spain)

^e Primary Care Centre Valls   (Spain)

^f Primary Healthcare Centre (CAP)   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h IISPV   (Spain)

ⁱ NONE   (Spain)

Author keywords

Amoxycillin; Amoxycillin clavulanate; Chronic obstructive pulmonary disease; Exacerbation; Primary care; Randomised controlled trial

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; THEOPHYLLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY FLOW; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY MEDICAL CARE; PRURITUS; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; SPAIN; SPIROMETRY; TREATMENT OUTCOME;

EID: 66149093898     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sobradillo Pena V, Miravitlles M, Gabriel R, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
2. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22.
3. Miravitlles M, Ferrer M, Pont A, et al. the IMPAC study group. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387-95.
4. Llor C, Molina J, Naberan K, et al. on behalf of the EVOCA study. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract. 2008;62:585-92.
5. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
6. Miravitlles M, Murio C, Guerrero T, et al. on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449-55.
7. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987;317:1309-14.
8. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1316-620.
9. Seemungal TA, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618-23.
10. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58:37-42.
11. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114-21.
12. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002;9:191-7.
13. Miravitlles M, Espinosa C, Fernández-Laso E, et al. Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-6.
14. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
15. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review. Respir Res. 2007;8:8-30.
16. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J. 2002;20(Suppl 36):9s-19s.
17. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis. A metaanalysis of randomized controlled trials. Chest. 2007;132:447-55.
18. Pérez-Trallero E, García de la Fuente C, García-Rey C, et al. Spanish Surveillance Group for Respiratory Pathogens. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother. 2005;49:1965-72.
19. Ferech M, Coenen S, Malhotra-Kumar S, et al. ESAC Project Group. European surveillance of antimicrobial consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother. 2006;58:401-7.
20. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138-80.
21. Miravitlles M, Monsó E, Mensa J, et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol. 2008;44:100-8
22. Llor C, Cots JM, Herreras A. Bacterial etiology of chronic bronchitis exacerbations treated by primary care physicians. Arch Bronconeumol. 2006;42:388-93.
23. Johnson PH, Macfarlane JT, Humphreys H. How is sputum microbiology used in general practice? Respir Med. 1996;90:87-8.
24. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345-52.
25. Miravitlles M, Llor C, Naberan K, et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med. 2005;99:955-65.
26. Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-64.
27. Alvarez-Sala JL, Kardos P, Martinez-Beltran J, et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50:1762-7.
28. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501-13.
29. Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please, Chest. 2004;125:811-13.
30. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis. 2007;1:61-76.
31. Bobadilla A, Guerra S, Sherrill D, et al. How accurate is the self-reported diagnosis of chronic bronchitis? Chest. 2002;122:1234-9.
32. Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med. 2000;94:18-27.
33. Evans AT, Husain S, Durairaj L, et al. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002;359:1648-54.
34. Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37:22-6.
35. Hoberman A, Paradise JL, Burch DL, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/ clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J. 1997;16:463-70.
36. Georgopoulos A, Borek M, Ridl W; the Amoxycillin Bronchitis Study Group. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 2001;47:67-76.
37. Mertens J, van Barneveld P, Asin H, et al. Double-blind randomised study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 1992;36:1456-9.
38. Monsó E, García-Aymerich J, Soler N, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003;131:799-804.
39. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-8.
40. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229-46.
41. Beekmann SE, Heilmann KP, Richter SS, et al. the GRASP Study. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streptococci in 2002-2003 Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents. 2005;25:148-56.
42. Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from communityacquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int J Antimicrob Agents. 2007;30:345-51.
43. Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. QJM. 1995; 88:61-8.
44. Miravitlles M, Murio C, Guerrero T; on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J. 2001;17:928-33.
45. Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006;61:337-42.